Not many small therapeutic molecules have been on the cover of TIME magazine. However, Gleevec
(Imatinib; Novartis) has had this honor on May 2001. See this web-article to gain more information about
Gleevec – https://www.nature.com/scitable/topicpage/gleevec-the- breakthrough-in-cancer-treatment-
565/. Using this and other literature, explain why Gleevec – a tyrosine kinase inhibitor – has been such a
trendsetter as a kinase inhibitor.